Summit Technology stock beams ahead 34.4% in July on anticipation of PRK approval.
This article was originally published in The Gray Sheet
Executive Summary
SUMMIT STOCK ASCENDS 34.4% IN JULY on investor speculation that the firm's excimer laser system is nearing approval at FDA for photorefractive keratectomy (PRK). Stock in Summit Technology climbed 13 points during the month to close at 50-3/4.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.